Biotech Innovator GNQ Moves North American Headquarters, Labs to Greenville
May 29, 2026
An innovative biotech company powered by its AI and quantum computing capabilities has moved its corporate headquarters and lab to Greenville
GNQ Insilico focuses on designing a platform to change how diseases like cancer and metabolic conditions are treated at the individual level. Founded in 2023 in Canada and previously headquartered in California, the company announced this week that it is relocating to Greenville, S.C., with initial lab operations within the Clemson University Biomedical Engineering Innovation Campus (CUBEInC), located at Prisma’s Patewood Campus, followed by its headquarters in the City of Greenville in months to come.
Valued at $500 million, GNQ plans to go public through a business combination with IB Acquisition Corp. The company is still developing job projections as they scale operations surrounding their public offering.
“We want Greenville to know that we are building something enduring here — not a satellite office, not a pilot program,” said Rehan Huda, founder and CEO of GNQ. “We chose this community because we believe in it, and our commitment to Greenville will grow as we grow. Greenville surprised us. When we began evaluating locations, we were looking for a city with the scientific infrastructure to support what we’re building – and we found something richer than that. Partners like the Greenville City EDC made that commitment tangible. Their direct support coupled with SCbio and SCRA was a meaningful signal that the city doesn’t just welcome strategic investments, it actively champions it.”
Through the use of artificial intelligence, advanced biological modeling and emerging computing technologies, GNQ is an innovative leader in the field. The move highlights Greenville’s growing life sciences ecosystem and coordinated recruitment efforts by the Greenville City Economic Development Corp., SCbio and the South Carolina Research Authority.
The SCRA is providing GNQ with a relocation grant of $50,000, and the City has committed job development grants of $1,500 for eligible jobs created in the first 5 years.
“This investment further strengthens Greenville’s rapidly expanding life sciences portfolio by bringing together the complementary strengths of Clemson’s engineering and data science talent with Prisma Health’s deep clinical expertise,” said Mayor Knox White. “By uniting these two powerhouse institutions, GNQ’s arrival amplifies the collaborative environment that makes Greenville uniquely positioned to lead in next‑generation biotechnology.”
“GNQ is exactly the type of global innovator that our City is seeking to attract and land, bringing novel technologies and high paying jobs to Greenville while further establishing our reputation as a rising hub for the life sciences industry,” said Sam Konduros, Greenville City EDC President & CEO. “We were honored to work with GNQ’s visionary corporate leaders, their amazing scientific team which recently relocated from Atlanta, and economic development partners to achieve this exciting opportunity.”
“Being embedded in an environment anchored by Prisma Health means our models can be informed by genuine clinical context,” said GNQ CTO Sudhir Saxena. “That’s invaluable. And the engineering and data science talent coming out of Clemson’s programs is exactly the kind of multidisciplinary pipeline we need to build the next generation of GNQ’s platform.”
The company uses artificial intelligence, quantum computing and digital twin technology to predict how individual patients respond to treatment before taking medication. The company says it is one of a very small number of companies globally doing this kind of work.